Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
about
Classification of drug molecules considering their IC50 values using mixed-integer linear programming based hyper-boxes method.The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies.First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds.First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer.Computational methods for the design of potent aromatase inhibitors.Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors.New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro.
P2860
Q33373829-8C9D8C99-1CC5-469E-B1E7-DAB88BADB019Q34564278-344613C7-5B64-4CB6-80CF-F7A194290213Q35675265-9A78A930-3B77-4F9A-A19E-AE997C2DFD1AQ36117828-B294DD4F-2055-4E2D-8D59-17396709A796Q36413805-5058070A-B330-42B4-9303-92670DCB6DC8Q36447393-33A33741-7DC8-4143-A5B4-802B3A4BDF2FQ38078417-CD78A595-90C9-47F1-AE37-0DF96081D288Q38783320-1D452B29-7667-4EDC-B98A-06301B06DEE7Q40045485-A6EF11D2-8717-497E-94D1-8C529458D7F8Q41544270-1FA2D9C8-9954-4A14-97E3-9ADBDAA8F506
P2860
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Three dimensional pharmacophor ...... s for prostate cancer therapy.
@en
Three dimensional pharmacophor ...... s for prostate cancer therapy.
@nl
type
label
Three dimensional pharmacophor ...... s for prostate cancer therapy.
@en
Three dimensional pharmacophor ...... s for prostate cancer therapy.
@nl
prefLabel
Three dimensional pharmacophor ...... s for prostate cancer therapy.
@en
Three dimensional pharmacophor ...... s for prostate cancer therapy.
@nl
P2093
P356
P1476
Three dimensional pharmacophor ...... ts for prostate cancer therapy
@en
P2093
Angela M H Brodie
Clive M Freeman
Omoshile O Clement
Rolf W Hartmann
Tadas S Vasaitis
Venkatesh D Handratta
P304
P356
10.1021/JM020576U
P407
P577
2003-06-01T00:00:00Z